These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11407195)

  • 1. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice.
    Zeppetella G; O'Doherty CA; Collins S
    Palliat Med; 2001 May; 15(3):243-6. PubMed ID: 11407195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice.
    Zeppetella G; O'Doherty CA; Collins S
    J Pain Symptom Manage; 2000 Aug; 20(2):87-92. PubMed ID: 10989246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of breakthrough pain by hospice patients and their caregivers.
    Fine PG; Busch MA
    J Pain Symptom Manage; 1998 Sep; 16(3):179-83. PubMed ID: 9769620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain.
    Portenoy RK; Bennett DS; Rauck R; Simon S; Taylor D; Brennan M; Shoemaker S
    J Pain; 2006 Aug; 7(8):583-91. PubMed ID: 16885015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.
    Zeppetella G
    J Pain Symptom Manage; 2008 May; 35(5):563-7. PubMed ID: 18258412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough pain in cancer patients.
    Zeppetella G
    Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):393-8. PubMed ID: 21227666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
    Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
    Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in pain management at the end of life.
    Miller KE; Miller MM; Jolley MR
    Am Fam Physician; 2001 Oct; 64(7):1227-34. PubMed ID: 11601805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrous oxide is not beneficial for breakthrough cancer pain.
    Enting RH; Oldenmenger WH; van der Rijt CC; Koper P; Lieverse J; Sillevis SP
    Palliat Med; 2002 May; 16(3):257-9. PubMed ID: 12047005
    [No Abstract]   [Full Text] [Related]  

  • 10. Breakthrough pain in opioid-treated patients with neuropathic pain.
    Simon S; Bennett DS; Rauck R; Taylor D; Shoemaker S
    J Opioid Manag; 2006; 2(6):347-52. PubMed ID: 17326597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthrough pain in children with cancer.
    Friedrichsdorf SJ; Finney D; Bergin M; Stevens M; Collins JJ
    J Pain Symptom Manage; 2007 Aug; 34(2):209-16. PubMed ID: 17553659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses.
    Pappagallo M; Dickerson ED; Hulka S
    Am J Hosp Palliat Care; 2000; 17(6):407-13. PubMed ID: 11886043
    [No Abstract]   [Full Text] [Related]  

  • 13. The management of pain in terminally ill cancer patients with difficulty swallowing.
    Coluzzi PH; Fairbairn BS
    Am J Hosp Palliat Care; 1999; 16(6):731-7. PubMed ID: 11094910
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer pain management: newer perspectives on opioids and episodic pain.
    Coluzzi PH
    Am J Hosp Palliat Care; 1998; 15(1):13-22. PubMed ID: 9468974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional variables in the appropriateness of fentanyl.
    Knowlton HL
    Am J Hosp Palliat Care; 2001; 18(3):160. PubMed ID: 11406891
    [No Abstract]   [Full Text] [Related]  

  • 16. Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate.
    Rhiner M; Palos G; Termini M
    Clin J Oncol Nurs; 2004 Oct; 8(5):507-12. PubMed ID: 15515284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pain assessment in terminally-ill cancer patients on admission in hospice and its modification after the first three days of care. A monocentric experience].
    Rozzi A; Scirocchi R; Fava A; Bordin F; D'Addario ME; Ranucci A; Lanzetta G; Di Miele D; Ferraccioli A; Terzoli L; Salerno M
    Clin Ter; 2011; 162(5):413-7. PubMed ID: 22041795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients.
    Weschules DJ; Bain KT; Reifsnyder J; McMath JA; Kupperman DE; Gallagher RM; Hauck WW; Knowlton CH
    Pain Med; 2006; 7(4):320-9. PubMed ID: 16898943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor pain therapy].
    Ohnesorge H; Siebrecht D; Gleim M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Jun; 38(6):403-34; quiz 435-7. PubMed ID: 12759876
    [No Abstract]   [Full Text] [Related]  

  • 20. Intermittent cancer pain: clinical importance and an updated cancer pain classification.
    Lasheen W; Walsh D; Sarhill N; Davis M
    Am J Hosp Palliat Care; 2010 May; 27(3):182-6. PubMed ID: 20008824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.